Immuno-oncology
Conference Coverage
Pembrolizumab does not surpass paclitaxel for gastric cancer
BARCELONA – The immune checkpoint inhibitor was not statistically superior to paclitaxel, but trends point to better outcomes with pembrolizumab,...
Conference Coverage
Blood and tissue TMB help predict checkpoint inhibition response in NSCLC
High bTMB and tTMB appear to have value as biomarkers for checkpoint inhibition response in patients with NSCLC, according to data presented at...
Conference Coverage
Avelumab does not add punch to ALK inhibitors for ALK+/– NSCLC
A combination of lorlatinib and avelumab showed good activity and acceptable safety against ALK-positive lung cancer, but no better efficacy than...
Conference Coverage
Novel antibody shifts ‘eat me/don’t eat me’ balance in refractory NHL
CHICAGO – Treatment with Hu5F9-G4 (5F9) produced “encouraging” antitumor activity in a phase 1b study of 22 patients.
From the Journals
Checkpoint inhibitor shows promise in advanced squamous-cell carcinoma
The PD-1 inhibitor cemiplimab has shown a response rate in about half of patients with advanced or metastatic cutaneous squamous-cell carcinoma....
Latest News
MRD-negative status signals better outcomes in CAR T–treated ALL
CHICAGO – The study sheds light on the value of transplant after treatment with CAR T cells.
From the Journals
Metastatic lung cancer: Pembrolizumab plus chemo prolongs survival
Overall survival at 12 months in NSCLC patients treated with pembrolizumab-combination therapy was 69.2%, compared with 49.4% in patients treated...
Conference Coverage
Pembrolizumab monotherapy shows activity in advanced recurrent ovarian cancer
CHICAGO – Antitumor activity appears strongest in patients with higher PD-L1 expression in their tumors.
From the Journals
Checkpoint inhibitors well tolerated by NSCLC patients with preexisting autoimmune disease
Flares during checkpoint inhibitor therapy were generally mild, and toxicity rates were only slightly increased in NSCLC patients with AID.
Conference Coverage
Cemiplimab impresses in advanced CSCC
CHICAGO – Investigational PD-1 checkpoint inhibitor is now under FDA review for marketing approval.
Conference Coverage
Multiple solid tumors targeted by concept CAR T
PITTSBURGH – Could this CAR T therapy become a viable option against pediatric solid tumors?